Coherus BioSciences Inc (CHRS) — Cash Flow-to-Debt Ratio
Coherus BioSciences Inc (CHRS) has a Cash Flow-to-Debt Ratio of -0.92x as of June 2026, meaning its operating cash flow of $-119.98 Million could theoretically repay -1% of its total liabilities ($130.34 Million) in one year. See CHRS free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Coherus BioSciences Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Coherus BioSciences Inc across 14 annual periods. For the full cash flow conversion analysis, see Coherus BioSciences Inc cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Coherus BioSciences Inc (2012–2025)
Year-by-year debt coverage analysis for Coherus BioSciences Inc. Check cash flow quality index of Coherus BioSciences Inc to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.70x | $-138.51 Million | $197.33 Million | ▼ -1893.6% |
| 2024 | -0.04x | $-20.44 Million | $580.52 Million | ▲ +83.4% |
| 2023 | -0.21x | $-174.88 Million | $823.03 Million | ▲ +45.5% |
| 2022 | -0.39x | $-241.12 Million | $618.26 Million | ▼ -506.0% |
| 2021 | -0.06x | $-37.43 Million | $581.61 Million | ▼ -123.4% |
| 2020 | 0.27x | $154.15 Million | $560.67 Million | ▲ +194.5% |
| 2019 | 0.09x | $28.36 Million | $303.71 Million | ▲ +108.1% |
| 2018 | -1.15x | $-159.27 Million | $138.06 Million | ▲ +23.9% |
| 2017 | -1.52x | $-200.29 Million | $132.08 Million | ▲ +4.4% |
| 2016 | -1.59x | $-252.54 Million | $159.13 Million | ▼ -222.3% |
| 2015 | -0.49x | $-107.99 Million | $219.31 Million | ▼ -147.9% |
| 2014 | -0.20x | $-23.93 Million | $120.46 Million | ▼ -215.7% |
| 2013 | 0.17x | $15.42 Million | $89.83 Million | ▲ +116.3% |
| 2012 | -1.05x | $-18.25 Million | $17.34 Million | — |